TABLE 6.
Change over time |
|||
Treatment | Baseline to 6 wk | 6 wk to 12 wk | Baseline to 12 wk |
Relative fat, % | |||
PB | −0.9 (−1.8, −0.1) | −0.4 (−1.3, 0.5) | −1.3 (−2.3, −0.4) |
WP | −1.2 (−2.1, −0.2) | −0.8 (−1.8, 0.2) | −1.9 (−2.9, −0.9) |
MDP | −1.0 (−2.0, −0.1) | −0.7 (−1.7, 0.3) | −1.7 (−2.7, −0.7) |
Fat mass, g | |||
PB | −360 (−1200, 510) | −120 (−1000, 770) | −480 (−1360, 410) |
WP | −590 (−1500, −320) | −570 (−1500, 380) | −1162 (−2100, −210) |
MDP | −560 (−1500, 350) | −590 (−1600, 380) | −1156 (−2100, −190) |
Fat mass trunk, g | |||
PB | −290 (−880, 300) | 17 (−580, 620) | −270 (−870, 330) |
WP | −340 (−960, 280) | −359 (−1000, 290) | −700 (−1300, −53) |
MDP | −360 (−980, 260) | −437 (−1100, 220) | −790 (−1500, −130) |
Values are means (95% CIs). Sample sizes/group at baseline, 6 wk, and 12 wk, respectively—MDP: n = 23, 20 and 18; PB: n = 23, 22, and 22; and WP: n = 22, 20, and 18. MDP, maltodextrin placebo; PB, soy-dairy protein blend; WP, whey protein.